Aberdeen Group’s Indivior Pharmaceuticals INDV Stock Holding History

Aberdeen Group’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-160,717	Closed	-$3.87M	–	959
2025 Q3	$3.87M	Buy	+160,717	New	+$3.36M	0.01%	724

Other funds holding INDV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aberdeen Group's INDV Position: Q4 2025 in Review

Aberdeen Group sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 160,717 shares — an estimated $3.87M sold.

Aberdeen Group first reported a position in INDV in Q3 2025 and held it in 1 quarter. The position peaked at $3.87M in Q3 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

Aberdeen Group reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Aberdeen Group sold 160,717 Indivior Pharmaceuticals shares in Q4 2025, an estimated $3.87M.
Aberdeen Group first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Aberdeen Group's Indivior Pharmaceuticals position peaked at $3.87M in Q3 2025.
259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.